<Page>
As filed with the Securities and Exchange Commission on April 24, 2002
File No. 333-_______
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------------
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
ISONICS CORPORATION
(Exact name of Registrant as specified in charter)
CALIFORNIA 77-0338561
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification No.)
5906 McIntyre Street
Golden, Colorado 80403
(303) 279-7900
(Address, including zip code and telephone number,
including area code of registrant's principal
executive offices)
James E. Alexander, President
5906 McIntyre Street
Golden, Colorado 80403
(303) 279-7900
(Name, address, including zip code and telephone number, including area code,
of agent for service)
It is requested that copies of all correspondence be sent to:
Herrick K. Lidstone, Jr., Esq.
Burns, Figa & Will, P.C.
6400 S. Fiddlers Green Circle, Suite 1030
Englewood, CO 80111
Telephone Number (303) 796-2666
Facsimile Number (303) 796-2777
Approximate date of commencement of proposed sale to public: As soon as
practicable after this Registration Statement becomes effective.
If the only securities being registered on this form are being offered pursuant
to dividend or interest reinvestment plans, please check the following box: [ ]
If any of the securities being registered on this form are to be offered on a
delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, other than securities offered only in connection with dividend or interest
reinvestment plans, check the following box: [xx]
1
<Page>
If this form is filed to register additional securities for an offering pursuant
to Rule 462(b) under the Securities Act, please check the following box and list
the Securities Act registration statement number of the earlier effective
registration statement for the same offering. [ ]
If this form is a post-effective amendment filed pursuant to Rule 462(c) under
the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [ ]
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. [ ]
CALCULATION OF REGISTRATION FEE
<Table>
<Caption>
Proposed maximum Proposed maximum
Title of Shares Amount to be aggregate price aggregate Amount of
to be registered registered per unit offering price Registration Fee
- ----------------------------------------------------------------------------------------------------
Common (1) 100,000 $1.25 $125,000 $3.76
Common (2) 50,000 $1.50 $75,000 $2.26
Common (3) 1,100,000 $1.00 $1,100,000 $ 33.11
Common (4) 200,000 $1.25 $250,000 $7.53
Common (5) 1,000,000 $1.00 $1,000,000 $ 30.10
--------- ---------- -------
Total 2,450,000 $2,550,000 $ 76.76
</Table>
The registration fee was calculated at the rate of $30.10 per $1,000,000 in
accordance with Fee Rate Advisory 9 for fiscal year 2002. Pursuant to Rule 416
of the Securities Act of 1933 and as required by Section 2(a) of the
registration rights agreement between Isonics and the Selling Stockholder, this
registration statement shall be deemed to cover such additional shares as may be
issued to the Selling Shareholder to prevent dilution resulting from future
dividends, stock distributions, stock splits or similar transactions.
(1) Shares which are issuable pursuant to the exercise of outstanding
warrants to purchase common stock at $1.25 per share. We issued these
common stock purchase warrants in March 2002 to vFinance Investments
and to certain of its principals as a placement fee pursuant to a
securities purchase agreement. The registration fee is based on the
exercise price of the warrants pursuant to Rules 457(a) and (g).
(2) Shares which are issuable pursuant to the exercise of outstanding
warrants to purchase common stock at $1.50 per share. We issued these
common stock purchase warrants in March 2002 to vFinance Investments
and to certain of its principals as an investment banking fee pursuant
to an investment banking agreement. The registration fee is based on
the exercise price of the warrants pursuant to Rules 457(a) and (g).
(3) Shares which are issuable pursuant to the conversion of Series 2002A
4% Convertible Promissory Notes at $1.00 per share. We issued notes
aggregating $1,000,000 to five accredited investors in March 2002.
Pursuant to the registration rights agreement, 110% of the number of
shares into which the notes would be convertible is being registered.
The registration fee is based on the conversion price of the notes
pursuant to Rules 457(a) and (g).
2
<Page>
(4) Shares which are issuable pursuant to the exercise of outstanding
common stock purchase warrants at $1.25 per share, which warrants were
granted in March 2002 in connection with the 2002A 4% Convertible
Promissory Note. The registration fee is based on the exercise price
of the warrants pursuant to Rules 457(a) and (g).
(5) Shares which are issuable pursuant to the exercise of warrants to
purchase common stock at $1.00 per share. We are obligated to issue
one warrant for each dollar in principal amount of the promissory
notes we repay in cash on or before its maturity date. The
registration fee is based on the exercise price of the Warrants
pursuant to Rules 457(a) and (g).
The registrant hereby amends this registration statement on such date or
dates as may be necessary to delay its effective date until the registrant shall
file a further amendment which specifically states that this registration
statement shall thereafter become effective in accordance with Section 8(a) of
the Securities Act of 1933 or until the registration statement shall become
effective on such date as the Commission, acting pursuant to said section 8(a),
may determine.
Information contained herein is subject to completion or amendment. A
registration statement relating to these securities has been filed with the
Securities and Exchange Commission. These securities may not be sold nor may
offers to buy be accepted prior to the time the registration statement becomes
effective. This prospectus shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of these securities
in any state in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such state.
3
<Page>
Preliminary Prospectus, Subject to completion, dated April 24, 2002
PROSPECTUS
----------
ISONICS CORPORATION
1,350,000 Shares of Common Stock
Offered for Resale by Selling Shareholders
This Prospectus relates to the sale to the public of up to 1,350,000 shares
of common stock of Isonics Corporation, a California corporation ("Isonics" or
"We"), which are being offered and sold by the selling shareholders named on
page 18 below, collectively referred to herein as the "Selling Shareholders."
The shares being offered by the Selling Shareholders include:
1,000,000 Shares issuable upon the conversion of or in payment of
Series 2002A 4% Convertible Promissory Notes at a price of
$1.00 per share; and
350,000 Shares issuable upon the exercise of outstanding common
stock purchase warrants exercisable at prices ranging from
$1.25 to $1.50.
1,000,000 Shares issuable upon the exercise of common stock purchase
warrants which we may be obligated to issue, exercisable at
$1.00 per share. IF WE ISSUE THESE WARRANTS, WE WILL NOT
ISSUE THE SHARES DESCRIBED IN THE FIRST ROW, ABOVE.
Our common stock is listed for trading on the Nasdaq SmallCap Market under
the symbol "ISON." On April 12, 2002, our common stock's last reported sale
price on the Nasdaq SmallCap Market was $1.19 per share.
We will not receive any money from the sale of the shares, although we will
receive from $0 to approximately $1,450,000 to the extent any of the Selling
Shareholders exercise outstanding warrants for cash. We will pay all expenses
incurred in connection with this offering except commissions and discounts,
which any of the Selling Shareholders may pay to underwriters, dealers, brokers
or agents. In addition, we will pay $2,500 to counsel to the Selling
Shareholders in connection with its review of this registration statement, and
an additional $1,500 in connection with his review of any post-effective
amendment.
The Selling Shareholders have advised us that none of them has made any
commitments with respect to the sale of the shares, but that they may sell the
shares from time-to-time on the Nasdaq SmallCap Market; in the over-the-counter
market outside of Nasdaq; or in negotiated transactions other than the Nasdaq
SmallCap Market or the over-the-counter market. Any of these sales may involve
block transactions. The Selling Shareholders have advised us that any of them
may sell the Shares at market prices at the time of sale, at prices related to
prevailing market prices at the time of sale, or at other negotiated prices.
THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. YOU SHOULD PURCHASE SHARES
ONLY IF YOU CAN AFFORD A COMPLETE LOSS. SEE "RISK FACTORS" BEGINNING ON PAGE 8.
We have not authorized anyone to give information or to make any representation
other than as contained in this prospectus in connection with the offering
described herein.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS
PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A
CRIMINAL OFFENSE.
The date of this prospectus is April 24, 2002.
4
<Page>
HOW TO OBTAIN ADDITIONAL INFORMATION
We file annual, quarterly, proxy statements, and other information with the
Securities and Exchange Commission (the "SEC"). You may read and copy any
document we have filed with the SEC in its public reference room at 450 Fifth
Street N.W. Washington, D.C. 20549. You may obtain information on the operation
of the public reference room by calling the SEC at 1-800-432-0330. The SEC
maintains a World Wide Web site on the Internet at http://www.sec.gov that
contains reports, proxy and information statements, and other information
regarding companies, including those that Isonics files electronically with the
SEC.
We also furnish Annual Reports to our shareholders that contain audited
financial information.
This prospectus is part of a registration statement (on Form S-3) we have
filed with the SEC relating to our Common Stock described in this prospectus. As
permitted by the SEC rules, this prospectus does not contain all of the
information contained in the registration, accompanying exhibits and schedules
we file with the SEC. You may refer to the registration, the exhibits and
schedules for more information about our Company and our Common Stock. The
registration statement, exhibits, and schedules are also available at the SEC's
public reference rooms or through its EDGAR database on the Internet.
You should rely only on the information contained or incorporated by
reference in this prospectus. Isonics has not authorized anyone to provide you
with information that is different from what is contained in this prospectus.
You should not assume that the information contained in this prospectus is
accurate as of any date other than the date set forth on the front cover of this
prospectus.
DOCUMENTS INCORPORATED BY REFERENCE
The SEC allows us to "incorporate by reference" the information in
documents we file with them, which means that we can disclose important
information to you by referring you to those documents. The information
incorporated by reference is considered to be part of this prospectus, and
information that we file later with the SEC will automatically update and
supersede this information. These documents provide a significant amount of
information about us. We incorporate by reference the documents listed below and
any future filings we will make with the SEC under Sections 13(a), 13(c), 14 or
15(d) of the Securities Exchange Act of 1934.
Our Annual Report on Form 10-KSB for the fiscal year ended April 30, 2001.
Our Quarterly Reports on Form 10-QSB for the quarters ended:
July 31, 2001, filed on September 12, 2001;
October 31, 2001, filed on December 14, 2001; and
January 31, 2002, filed on March 12, 2002.
Our Current Reports on Form 8-K, reporting events of:
July 26, 2001;
January 8, 2002;
February 28, 2002; and
March 22, 2002.
5
<Page>
Our Registration Statement on Form 8-A filed on August 20, 1997,
registering our common stock and other securities registered under the
Securities Exchange Act of 1934, as amended by Forms 8-A filed on March 10,
2000, May 30, 2000, May 11, 2001, May 14, 2001, and August 1, 2002.
We also incorporate by reference any future filings we may make with the
Securities and Exchange Commission under Sections 13(a), 13(c), 14, and 15(d) of
the Securities Exchange Act before the termination of this offering.
We have not authorized any person to give any information, which is
inconsistent with information contained in or incorporated into this prospectus.
You should not rely on any inconsistent information.
Neither the delivery of this Prospectus nor any sale made hereunder shall
under any circumstances create any implication that the information contained
herein is correct as of any time subsequent to the date hereof.
You may request a copy of these filings or a copy of any or all of the
documents referred to above which have been or may be incorporated in this
Prospectus by reference, at no cost, by writing us or calling us at the
following address and telephone number:
Isonics Corporation
5906 McIntyre Street
Golden, CO 80403
Telephone No.: (303) 279-7900
Facsimile No.: (303) 279-7300
Additionally, the documents are available electronically in the EDGAR
database on the web site maintained by the SEC. You can find this information at
http://www.sec.gov.
NOTE OF CAUTION REGARDING FORWARD-LOOKING STATEMENTS
In our effort to make the information in this prospectus more meaningful,
this prospectus contains both historical and forward-looking statements. All
statements other than statements of historical fact are forward-looking
statements within the meanings of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Forward-looking statements
in this prospectus are not based on historical facts, but rather reflect the
current expectations of our management concerning future results and events.
The forward-looking statements generally can be identified by the use of
terms such as "believe," "expect," "anticipate," "intend," "plan," "foresee,"
"likely," "will" or other similar words or phrases. Similarly, statements that
describe our objectives, plans or goals are, or may be, forward-looking
statements.
Forward-looking statements involve known and unknown risks, uncertainties
and other factors that may cause the actual results, performance or achievements
of Isonics to be different from any future results, performance and achievements
expressed or implied by these statements. You should review carefully all
information, including the financial statements and the notes to the financial
statements
6
<Page>
included in this prospectus. In addition to the factors discussed under "Risk
Factors," the following important factors could affect future results, causing
the results to differ materially from those expressed in the forward-looking
statements in this prospectus:
o demand for, and acceptance of, our products;
o changes in development, distribution and supply relationships;
o the impact of competitive products and technologies;
o the risk of operations in Russia, the Republic of Uzbekistan, and the
Republic of Georgia;
o dependence on future product development;
o the possibility of future customer concentration;
o our dependence on key personnel;
o the volatility of our stock price; and
o the impact of new technologies.
These factors are not necessarily all of the important factors that could
cause actual results to differ materially from those expressed in the
forward-looking statements in this prospectus. Other unknown or unpredictable
factors also could have material adverse effects on the future results of
Isonics. The forward-looking statements in this prospectus are made only as of
the date of this prospectus and Isonics does not have any obligation to publicly
update any forward-looking statements to reflect subsequent events or
circumstances. Isonics cannot assure you that projected results will be
achieved.
PROSPECTUS SUMMARY
YOU SHOULD READ THE FOLLOWING SUMMARY TOGETHER WITH THE MORE DETAILED
INFORMATION REGARDING OUR COMPANY AND THE COMMON STOCK BEING OFFERED BY THE
SELLING SHAREHOLDERS, AS WELL AS OUR FINANCIAL STATEMENTS AND NOTES TO THOSE
STATEMENTS APPEARING IN THE DOCUMENTS INCORPORATED BY REFERENCE.
ISONICS CORPORATION
Isonics is an advanced materials and technology company, which develops and
commercializes products based on enriched stable and radioactive isotopes. Our
common stock is traded on the Nasdaq SmallCap Market under the symbol "ISON."
The market for our stock has historically been characterized generally by broad
price and volume volatility. We cannot give any assurance that a stable trading
market will develop for our stock.
The address of our principal executive offices and our telephone and
facsimile numbers at that address are as set forth on the previous page.
THE SECURITIES
Currently our common stock, Class B common stock purchase warrants, and our
Class C common stock purchase warrants are registered under the Securities
Exchange Act of 1934, as amended and are quoted under the following symbols:
Common stock: ISON
Class B warrants: ISONL
Class C warrants: ISONZ
7
<Page>
As of April 12, 2002, there were 10,824,812 shares of our Common Stock
outstanding. If all of the warrants and Series 2002A 4% convertible promissory
notes described in this Prospectus are exercised or converted (of which there
can be no assurance), there would be an additional 1,350,000 shares of common
stock outstanding. See "Description of Securities" commencing on page 22, of
this Prospectus.
THE OFFERING
The Selling Shareholders are offering up to 1,350,000 shares of common
stock (the "Shares"). Of these:
100,000 shares are issuable to seven Selling Shareholders should they
exercise outstanding common stock purchase warrants exercisable at a price of
$1.25 per share;
50,000 shares are issuable to seven Selling Shareholders should they
exercise outstanding warrants to purchase common stock exercisable at a price of
$1.50 per share;
1,000,000 shares are issuable to five Selling Shareholders should they
convert Series 2002A 4% Convertible Promissory Notes into common stock at a
price of $1.00 per share; and
200,000 shares are issuable to five Selling Shareholders should they
exercise outstanding warrants to purchase common stock exercisable at a price of
$1.25 per share, which warrants were granted in connection with the 2002A 4%
Convertible Promissory Notes.
We have a right to repay the promissory notes in cash, but if we do so, we
have an obligation to issue up to an additional 1,000,000 common stock purchase
warrants (exercisable at $1.00) at the rate of one warrant for each $1.00 in
principal cash payment. If we issue these warrants, we will not issue the
1,000,000 shares to holders of the Series 2002A 4% Convertible Promissory Notes
because they will not have converted those Notes.
The Selling Shareholders will receive all of the proceeds from the offer
and sale of the Shares. We will receive proceeds to the extent any of the
Selling Shareholders exercise the Warrants for cash.
We will pay the costs related to the filing of the registration statement
in which this Prospectus is included. The Selling Shareholders will pay their
own expenses related to the offer and sale of the Shares, including any
underwriter discounts or commissions.
RISK FACTORS
Any person considering the purchase of Isonics' common stock or warrants
should understand that such purchase and ownership involves a high degree of
risk. You should purchase our securities only if you can afford a complete loss
of your investment. Many of these risks are set forth in more detail in the
documents incorporated by reference, each of which should be reviewed before
making an investment in our securities. Among the risks that you should consider
in determining whether to invest in our securities are the following:
8
<Page>
UNLESS WE ARE ABLE TO DEVELOP AND SELL NEW PRODUCTS PROFITABLY, WE MAY BE UNABLE
TO REMAIN COMPETITIVE, FURTHERING THE LIKELIHOOD THAT OUR LOSSES AND NEGATIVE
CASH FLOW WILL CONTINUE
We have not operated profitably since our 1996 fiscal year. We recognized
net income for the year ended April 30, 2000, only because of the gain
recognized on the sale of our depleted zinc assets to Eagle-Picher. In addition,
through November 30, 1999, our revenues had historically been derived from our
depleted zinc operations.
As a consequence of our sale of the depleted zinc operations, our
operations and our ability to generate revenues are more heavily dependent upon
our ability to develop new products using stable and radioactive isotopes, and
to market and sell those products profitably. We may be unable to develop
products that can be profitably marketed and sold, which may prevent us from
paying creditors as debts are due, and, in turn, may materially impact our
ability to continue our business operations.
WE ARE CRITICALLY SHORT OF WORKING CAPITAL FOR OUR OPERATIONS FOR A NUMBER
OF REASONS. THESE REASONS INCLUDE:
o Continuing operating losses and negative cash flow;
o Eagle-Picher's failure to pay the cash amounts it owes to us under our
contractual arrangements; and
o Eagle-Picher's failure to deliver 200 kilograms of silicon-28 to us,
resulting in our need to use our capital to purchase the silicon-28
from other suppliers and a delay in our ability to complete our
research and development program for silicon-28, resulting in a delay
in our ability to achieve revenues from silicon-28.
It is possible that the following circumstances may develop and may further
adversely impact our available working capital and materially impact our
ability to continue our business operations:
o unanticipated expenses in developing our new products or in producing
or marketing our existing products;
o the necessity of having to protect and enforce our intellectual
property rights;
o technological and market developments;
o a corporate decision to expand our production capacity through capital
investment or acquisition; and
o the possibility that we may suffer an adverse decision in our
Eagle-Picher arbitration as described in the documents incorporated by
reference, especially (but not exclusively) our annual report on Form
10-KSB.
We may not be able to obtain equity or debt financing on reasonable terms
when we need such financing. The unavailability of additional financing, when
needed, could have a material adverse effect on our business.
9
<Page>
Our current working capital shortage and operating losses resulted in our
auditors including an explanatory paragraph in their opinion on our financial
statements as of and for the year ended April 30, 2001 that such factors raised
a substantial doubt regarding our ability to continue as a going concern.
WE HAVE RAISED CAPITAL DURING THE NINE MONTHS ENDED JANUARY 31, 2002 AND THE
YEAR ENDED APRIL 30, 2001, WHICH HAS RESULTED IN DILUTION TO OUR EXISTING
SHAREHOLDERS. THIS WAS NECESSARY IN ORDER TO PROVIDE NECESSARY WORKING CAPITAL
AND WE MAY BE REQUIRED TO RAISE ADDITIONAL CAPITAL, WHICH MAY RESULT IN
SUBSTANTIAL ADDITIONAL DILUTION
During the nine months ended January 31, 2002, we issued 494,849 shares of
common stock for approximately $473,000 as the result of the exercise of common
stock warrants. Included in the exercised common stock warrants were 202,500
Class B warrants. Subsequently we raised an additional $1,000,000 which resulted
in the issuance of the Series 2002A promissory notes and the common stock
purchase warrants being registered in this prospectus.
On December 13, 2000, we sold 337,500 units consisting of one share of our
common stock and two Class B warrants for $675,000 to a group of accredited
investors. As a result of subsequent adjustments, we issued an additional
112,504 shares of common stock and an additional 675,000 Class B warrants.
The exercise of outstanding common stock purchase warrants may provide us
with some additional financing, but it is likely that no warrants will be
exercised unless the market price is in excess of the exercise price ($1.50 per
share for the Class B warrants, and $2.50 per share for the Class C warrants,
and prices ranging from $1.50 to $9.57 for other outstanding warrants). Any such
exercise will result in additional dilution to our shareholders.
Furthermore, our efforts to raise working capital have resulted in dilution
adjustments to our outstanding common stock warrants associated with the
preferred stock private placement completed on July 29, 1999. These dilution
adjustments did not result in any additional investment in Isonics, but resulted
in the issuance of 788,955 additional common stock warrants for no additional
consideration and reduced the exercise price to $2.79 for all related common
stock warrants.
In addition to anti-dilution rights, there are provisions associated with
the preferred stock private placement completed on July 29, 1999 that if
triggered, would reduce the current conversion price and effectively allow the
preferred shares to convert to common stock at a ratio greater than a one for
one basis. As a result of the issuance of the Series 2002A 4% convertible
promissory notes at $1.00 per share, the preferred stock is now convertible at
approximately 1.50 shares of common stock for each share of Series A Convertible
Preferred Stock outstanding. As of April 12, 2002 there were 963,666 shares of
Series A Convertible Preferred Stock outstanding.
If we are successful in raising additional working capital, our
shareholders may incur additional dilution adjustments.
10
<Page>
OPERATIONS IN RUSSIA, THE REPUBLIC OF UZBEKISTAN, AND THE REPUBLIC OF GEORGIA
MAY BE DISRUPTED BECAUSE OF A VOLATILE POLITICAL AND ECONOMIC CLIMATE BEYOND OUR
CONTROL, WHICH COULD ADVERSELY AFFECT OUR SUPPLY OF RAW MATERIALS
Operations in Russia, the Republic of Uzbekistan, and the Republic of
Georgia entail risks. The former republics of the Soviet Union including
Uzbekistan and Georgia are experiencing political, social and economic change as
they obtain independence from the former central government in Moscow. Some of
the republics, including Russia, Uzbekistan and Georgia, are attempting to
transition from a central-controlled economy toward a market-based economy.
These changes have involved, in some cases, armed conflict and the risk of
continued instability has increased since the terrorist attacks on the United
States of September 11, 2001. Although Uzbekistan borders Afghanistan, the
conflict in Afghanistan has not impacted our supply of isotopes. Political or
economic instability in these republics may continue or worsen. The price,
availability, quality, quantity, ability to export and supply of stable and
radioactive isotopes could be directly affected by political, economic and
military conditions in Russia, Uzbekistan and Georgia.
We are dependent on suppliers from Russia, Uzbekistan, and Georgia for
approximately 90% of our stable isotopes and 90% of our radioisotopes.
Accordingly, our operations could be materially adversely affected if
hostilities in Russia, Uzbekistan, or Georgia should occur, if trade between
Russia, Uzbekistan and/or Georgia and the United States were interrupted or
ceased, if political conditions in Russia, Uzbekistan or Georgia disrupt
transportation or processing of our goods, if laws or government policies
concerning foreign business operations in Russia, Uzbekistan or Georgia change
substantially, or if tariffs are introduced.
BECAUSE WE DEPEND UPON FEW CUSTOMERS FOR A SIGNIFICANT PORTION OF OUR REVENUES,
OUR BUSINESS MAY BE MATERIALLY AND ADVERSELY AFFECTED IF WE LOSE ANY ONE OF
THESE CUSTOMERS
Three customers (Perkin Elmer Life Sciences, Eastern Isotopes, and Reviss
Ltd.) accounted for approximately 24%, 19% and 5%, respectively, of net revenues
for the nine months ended January 31, 2002. Two customers (Perkin Elmer Life
Sciences and Reviss Ltd.) accounted for approximately 38% and 11%, respectively,
of the German segment's revenue for the nine months ended January 31, 2002. Five
customers (Perkin Elmer Life Sciences, Eastern Isotopes, Reviss Ltd.,
Commisariat and IPL) accounted for approximately 16%, 9%, 7%, 5% and 4%,
respectively of net revenues for the year ended April 30, 2001. Two customers
(Perkin Elmer Life Sciences and Reviss Ltd.) accounted for approximately 24% and
11%, respectively of the German segment's net revenues for the year ended April
30, 2001. While our goal is to diversify our customer base, we expect to
continue to depend upon a relatively small number of customers for a significant
percentage of our revenues for the foreseeable future. Significant reductions in
sales to any of our large customers have had, and may in the future have, a
material adverse effect on us by reducing our revenues and our gross margins.
Present or future customers could terminate their purchasing patterns with us or
significantly change, reduce or delay the amount of isotope or other products
ordered from us.
11
<Page>
IF DEMAND FOR OUR PRODUCT GROWS SUDDENLY, WE MAY LACK THE RESOURCES TO MEET
DEMAND OR WE MAY BE REQUIRED TO INCREASE OUR CAPITAL SPENDING SIGNIFICANTLY
We have experienced, and may again experience, periods of rapid growth that
place a significant strain on our financial and managerial resources. Through
our marketing efforts we have increased the number and type of products we offer
to our customers in our effort to replace the cash flow reduction that occurred
as a result of the sale of our depleted zinc operations, and we are continuing
to look for new products to offer. Through our research and development efforts
we are also attempting to develop additional products and lines of business. Our
ability to manage growth effectively, particularly given our increasing scope of
operations, will require us to continue to implement and improve our management,
operational and financial information systems, and will require us to develop
the management skills of our personnel and to train, motivate and manage our
employees. Our failure to effectively manage growth could increase our costs of
operations and reduce our margins and liquidity, which could have a material
adverse effect on our business, financial condition and results of operations.
BECAUSE WE ARE DEPENDENT UPON OUR KEY PERSONNEL FOR OUR FUTURE SUCCESS, IF WE
FAIL TO RETAIN OR ATTRACT KEY PERSONNEL, OUR BUSINESS WILL BE ADVERSELY AFFECTED
Our future success will depend in significant part upon the continued
service of our key technical, sales and senior management personnel, including
James E. Alexander, our President and Chief Executive Officer; Boris
Rubizhevsky, our Senior Vice President, Isotope Production and Supply; Daniel
Grady, Vice President, Life Sciences, Stephen Burden, Vice President,
Semiconductor Materials, and Hans Walitzki, Vice President, Advanced Wafer
Technology. We have obtained $1,000,000 of key man life insurance on the lives
of Mr. Alexander and Mr. Rubizhevsky. Currently neither Mr. Alexander nor Mr.
Rubizhevsky are covered by employment agreements and the compensation committee
has not yet determined if they will issue new contracts. Mr. Grady and Mr.
Burden are covered by employment agreements with an indefinite term that
provides at-will employment, terminable at any time by either party. Mr.
Walitzki is covered by an employment agreement through November 2006.
We believe that our future success will also depend upon our ability to
attract and retain other qualified personnel for our operations. The failure to
attract or retain such persons could materially adversely affect our business,
financial condition and results of operations.
WE MAY NOT BE ABLE TO PROTECT OUR INTELLECTUAL PROPERTY, WHICH WOULD REDUCE OUR
COMPETITIVE ADVANTAGE
We rely primarily on a combination of patents and patent applications,
trade secrets, confidentiality procedures, and contractual provisions to protect
our technology. Despite our efforts to protect our technology, unauthorized
parties may attempt to copy aspects of our products or to obtain and use
information that we regard as proprietary. Policing unauthorized use of our
technology and products is difficult. In addition, the laws of many countries do
not protect our rights to information, materials and intellectual property that
we regard as proprietary, and that are protected under the laws of the United
States. We may not be able to protect our proprietary interests, or our
competitors may independently develop similar technology or intellectual
property. If either one of these situations occurs, we may lose existing
customers and our business may suffer.
12
<Page>
The validity of any of the patents licensed to us, or that may in the
future be owned by us, may not be upheld if challenged by others in litigation.
Further, our products or technologies, even if covered by our patents, may
infringe upon patents owned by others. We could incur substantial costs in
defending suits brought against us, or any of our licensors, for infringement,
in suits by us against others for infringement, or in suits contesting the
validity of a patent. Any such proceeding may be protracted. In any suit
contesting the validity of a patent, the patent being contested would be
entitled to a presumption of validity and the contesting party would be required
to demonstrate invalidity of such patent by clear and convincing evidence. If
the outcome of any such litigation were adverse to our interests, our liquidity
and business operations would be materially adversely affected.
WE FACE TECHNOLOGICAL CHANGE AND INTENSE COMPETITION BOTH DOMESTICALLY AND
INTERNATIONALLY WHICH MAY ADVERSELY AFFECT OUR ABILITY TO SELL OUR PRODUCTS
PROFITABLY
Although we do not believe that any entity produces a complete range of
stable enriched isotopes for commercial sale, many of our competitors have
significantly greater funding than do we and may be able to develop products
which are competitive with our products.
Further, it is possible that future technological developments may occur.
The market for our isotope products is characterized by rapidly evolving
technology and continuing process development. Our future success will depend
upon our ability to develop and market isotope products that meet changing
customer and technological needs on a cost effective and timely basis.
Specifically, the failure by Eagle-Picher to provide us with silicon-28 has
hindered, and may continue to hinder, our research and development activities,
which then negatively affects our ability to remain competitive. If we fail to
remain competitive by anticipating the needs of our customers and our customers
contract with other suppliers, our revenues and resulting cash flow could be
materially and adversely affected.
WE COULD BE SUBJECT TO ENVIRONMENTAL REGULATION BY FEDERAL, STATE AND LOCAL
AGENCIES, INCLUDING LAWS THAT IMPOSE LIABILITY WITHOUT FAULT, WHICH COULD
PRODUCE WORKING CAPITAL SHORTAGES AND LESSEN SHAREHOLDERS' EQUITY
We could become subject to a variety of federal, state, and local
environmental regulations relating to the use, storage, discharge and disposal
of hazardous chemicals used during the isotope product delivery and
manufacturing process, although we do not believe that there is any such
regulation directly applicable to our current operations. Regulations that
become applicable to our operations in the future could restrict our ability to
expand our facilities or could require us to acquire costly equipment or to
incur other significant expenses to comply with governmental regulations.
Historically, our costs of compliance with environmental regulations have not
been significant. In the quarter ended October 31, 2000, we recognized a
$270,000 expense to remediate the Golden, Colorado facility. The lease and this
liability were assumed by the buyers of International Process Research
Corporation effective February 1, 2001.
WE ARE CONTROLLED BY ONLY A FEW OFFICERS AND DIRECTORS AND, CONSEQUENTLY,
PURCHASERS OF OUR SHARES WILL HAVE VERY LITTLE ABILITY TO ELECT OR SIGNIFICANTLY
INFLUENCE OUR MANAGEMENT
Even if all outstanding warrants and stock options are exercised and
convertible securities are exchanged for common stock, our directors and
officers will beneficially own approximately 27.4% of the outstanding shares of
common stock as of April 12, 2002, and, accordingly, may have the ability to
elect a majority of the directors of Isonics and otherwise significantly
influence the company. As a result, such persons, acting together, will have the
ability to significantly influence all matters submitted to
13
<Page>
stockholders for approval, including the election and removal of directors and
any merger, consolidation or sale of substantially all of our assets, and to
influence our management and affairs. Such concentration of ownership may have
the effect of delaying, deferring or preventing a change in control, impeding a
merger, consolidation or takeover or other business combination involving us or
discouraging a potential acquirer from making a tender offer or otherwise
attempting to obtain control of our business, even if such a transaction would
be beneficial to other stockholders.
WE RISK EXPOSING OURSELVES TO AN ABOVE-POLICY LIMIT PRODUCT LIABILITY CLAIM,
WHICH COULD ADVERSELY AFFECT OUR WORKING CAPITAL, SHAREHOLDERS' EQUITY AND
PROFITABILITY
The use of our radioisotopes in radiopharmaceuticals and in clinical trials
may expose us to potential product liability risks that are inherent in the
testing, manufacture, marketing, and sale of human diagnostic and therapeutic
products. We currently have product liability insurance; however, there is a
risk that our insurance would not cover completely or would fail to cover a
claim, in which case we may not have the financial resources to satisfy such
claims, and the payment of claims would require us to use funds that are
otherwise needed to conduct our business and make our products.
OUR COMMON STOCK IS VULNERABLE TO PRICING AND PURCHASING ACTIONS THAT ARE BEYOND
OUR CONTROL AND, THEREFORE, PERSONS ACQUIRING OUR SHARES OR WARRANTS MAY BE
UNABLE TO RESELL THEIR SHARES OR WARRANTS AT A PROFIT AS A RESULT OF THIS
VOLATILITY
The trading price of our securities has been subject to wide fluctuations
in response to quarter-to-quarter variations in our operating results, our
announcements of technological innovations or new products by us or our
competitors, and other events and factors. The securities markets themselves
have from time to time and recently experienced significant price and volume
fluctuations that may be unrelated to the operating performance of particular
companies. Announcements of delays in our testing and development schedules,
technological innovations or new products by us or our competitors and
developments or disputes concerning patents or proprietary rights could have a
significant and adverse impact on such market prices. Regulatory developments in
the United States and foreign countries, public concern as to the safety of
products containing radioactive compounds, economic and other external factors,
all affect the market price of our securities. IN ADDITION, THE REALIZATION OF
ANY OF THE RISKS DESCRIBED IN THESE "RISK FACTORS" COULD HAVE A SIGNIFICANT AND
ADVERSE IMPACT ON SUCH MARKET PRICES.
SEC PENNY STOCK REGULATIONS MAY LIMIT THE ABILITY TO TRADE OUR SECURITIES ON THE
NASDAQ SMALL CAP MARKET
Although our common stock is currently quoted on the Nasdaq SmallCap Stock
Market, our common stock has in the past been subject to additional disclosure
requirements for penny stocks mandated by the Securities Enforcement Remedies
and Penny Stock Reform Act of 1990. The SEC Regulations generally define a penny
stock to be an equity security that has a market price of less than $5.00 per
share. We have, at times in the past, been included within the SEC Rule 3a-51
definition of a penny stock. When our common stock is considered to be a "penny
stock", trading is covered by Rule 15g-9 promulgated under the Securities
Exchange Act of 1934, for non-Nasdaq and non-national securities exchange listed
securities.
Under this rule, broker-dealers who recommend such securities to persons
other than established customers and accredited investors must make a special
written disclosure to, and suitability determination for, the purchaser and
receive the purchaser's written agreement to a transaction prior to sale. The
regulations on penny stocks limit the ability of broker-dealers to sell our
common stock and thus the ability of purchasers of our common stock to sell
their securities in the secondary market. To the extent we are able to maintain
our
14
<Page>
listing on the Nasdaq SmallCap Stock Market, we will not be subject to these
penny stock rules. Reasons for being unable to maintain our listing on the
Nasdaq SmallCap Stock Market include:
o the inability to maintain a bid price for our common stock of $1.00
for the requisite period of time and
o the inability to maintain either the minimum Stockholders' equity,
market capitalization or net income along with the required number of
market makers and shareholders necessary for listing.
We currently satisfy all requirements for continued listing on the Nasdaq
SmallCap Market, although the volatility of our stock prices and our financial
condition may result in our failing to meet Nasdaq's requirements at some future
date. The time required for meeting these thresholds is contingent on any action
(or inaction) by Nasdaq with respect to our listing.
FUTURE SALES OF OUR COMMON STOCK MAY CAUSE OUR STOCK PRICE TO DECLINE
Our stock price may decline by future sales of our shares or the perception
that such sales may occur. As of April 12, 2002, approximately 5,616,467 shares
of common stock held by existing stockholders constitute "restricted shares" as
defined in Rule 144 under the Securities Act. The restricted shares may only be
sold if they are registered under the Securities Act, or sold under Rule 144, or
another exemption from registration under the Securities Act.
Approximately 85% of the restricted shares of our common stock are either
eligible for sale pursuant to Rule 144 or have been registered under the
Securities Act for resale by the holders. We are unable to estimate the amount,
timing, or nature of future sales of outstanding common stock. Sales of
substantial amounts of our common stock in the public market may cause the
stock's market price to decline.
OUTSTANDING SERIES A PREFERRED STOCK, OPTIONS AND WARRANTS MAY MAKE IT DIFFICULT
FOR US TO OBTAIN ADDITIONAL CAPITAL ON REASONABLE TERMS
As of April 12, 2002, we had outstanding preferred stock and promissory
notes convertible into, and options and warrants to purchase, an aggregate of
10,192,204 shares of common stock. As long as these shares of Series A
convertible preferred stock and convertible promissory notes remain outstanding
and the options and warrants remain unexercised, the terms under which we could
obtain additional capital may be adversely affected because any new investors
will perceive that these lower priced securities offer a risk of substantial
potential dilution. Depending on the market price for our common stock as
reported by Nasdaq and other sources, new investors frequently prefer to
negotiate prices that are at or below the conversion price or exercise price of
existing securities.
PROVISIONS IN OUR CHARTER DOCUMENTS COULD PREVENT OR DELAY A CHANGE IN CONTROL,
WHICH COULD DELAY OR PREVENT A TAKEOVER
Our Articles of Incorporation authorize the issuance of "blank check"
preferred stock with such designations, rights, and preferences, as may be
determined by our Board of Directors. Accordingly, the Board of Directors may,
without shareholder approval, issue shares of preferred stock with dividend,
liquidation, conversion, voting, or other rights that could adversely affect the
voting power or other rights of the holders of our common stock. Preferred stock
could also be issued to discourage, delay, or prevent a change in our control,
although we do not currently intend to issue any additional series of our
preferred stock.
15
<Page>
PROVISIONS IN OUR BYLAWS PROVIDE FOR INDEMNIFICATION OF OFFICERS AND DIRECTORS
TO THE FULL EXTENT PERMITTED BY CALIFORNIA LAW, WHICH COULD REQUIRE US TO DIRECT
FUNDS AWAY FROM OUR BUSINESS AND PRODUCTS
Our Bylaws provide for indemnification of officers and directors to the
full extent permitted by California law, our state of incorporation. We may be
required to pay judgments, fines, and expenses incurred by an officer or
director, including reasonable attorneys' fees, as a result of actions or
proceedings in which such officers and directors are involved by reason of being
or having been an officer or director. Funds paid in satisfaction of judgments,
fines and expenses may be funds we need for the operation of our business and
the development of our products, thereby affecting our ability to attain
profitability. This could cause our stock price to drop.
THE FORWARD-LOOKING STATEMENTS WE MAKE IN THIS PROSPECTUS MAY PROVE TO BE
INACCURATE
In our effort to make the information in this report more meaningful, this
report contains both historical and forward-looking statements. All statements
other than statements of historical fact are forward-looking statements within
the meanings of Section 27A of the Securities Act of 1933, and Section 21E of
the Securities Exchange Act of 1934. Forward-looking statements in this report
are not based on historical facts, but rather reflect the current expectations
of our management concerning future results and events.
The forward-looking statements generally can be identified by the use of
terms such as "believe," "expect," "anticipate," "intend," "plan," "foresee,"
"likely," "will" or other similar words or phrases. Furthermore, statements that
describe our objectives, plans, or goals are, or may be, forward-looking
statements.
Forward-looking statements involve known and unknown risks, uncertainties
and other factors which may cause our actual results, performance or
achievements to be different from any future results, performance and
achievements expressed or implied by these statements.
These factors are not necessarily all of the important factors that could
cause actual results to differ materially from those expressed in the
forward-looking statements in this prospectus. Other unknown or unpredictable
factors also could have material adverse effects on our future results.
WHO WE ARE
Our corporate name is "Isonics Corporation." We are an advanced materials
and technology company. We are developing and we anticipate commercializing
products created from materials, including materials whose natural isotopic
ratios have been modified as well as non-isotopic (natural) materials. An
isotope is one of two or more species (or nuclides) of the same chemical element
that differ from one another only in the number of neutrons in the atom's
nucleus. The different number of neutrons can create significantly different
nuclear properties. The most well-known of these properties is radioactivity.
Radioactive isotopes (or radioisotopes) can be found in nature. Most of our
radioisotopes, however, are man-made. Stable isotopes, as distinguished from
radioisotopes, are not radioactive. Several manufacturers, located primarily in
republics that once were part of the Soviet Union, produce these isotopes. We
buy these isotopes from the manufacturers and resell them in the form of common
chemical compounds. For example, oxygen-18 is sold as water, and carbon-13 is
sold as carbon dioxide. Today our business addresses the material needs of two
primary markets:
16
<Page>
o life sciences (involving isotopic materials) and
o semiconductor materials and products (including both isotopic and
non-isotopic materials).
While we currently are focusing on these two markets, we continue to
evaluate other applications for both stable and radioisotopes and non-isotopic
materials. We also sell isotopes for use in basic scientific research and
industrial applications. We believe our core competency is our ability to
identify, develop, source, and commercialize products and services based on
isotopically engineered materials as well as non-isotopic semi-conductor
materials.
We were formed in March 1992, as a partnership, and were subsequently
incorporated in California in March 1993, as A&R Materials, Inc. In September
1996, we changed our name to Isonics Corporation. The common stock of Isonics is
traded on the Nasdaq SmallCap Market under the symbol "ISON." The market for our
stock has historically been characterized generally by low volume, and broad
price and volume volatility. We cannot give any assurance that a stable trading
market will develop for our stock or our warrants.
The address of our principal executive offices and our telephone and
facsimile numbers at that address are:
Isonics Corporation
5906 McIntyre Street
Golden, Colorado 80403
Telephone No.: (303) 279-7900
Facsimile No.: (303) 279-7300
USE OF PROCEEDS
The Selling Shareholders named in this Prospectus will receive all proceeds
from the sale of the shares offered and sold under this Prospectus.
If and to the extent any Selling Shareholder exercises any of the
outstanding warrants for cash, we will receive proceeds equal to the aggregate
exercise price of the warrants, which may be $0.00 or as much as $1,450,000, if
all of the warrants are exercised for cash. The warrants are described under the
caption "Selling Shareholders." Any proceeds we may receive from the exercise of
any warrants will be used for working capital. We cannot offer any assurance
that any warrants will be exercised.
The Selling Shareholders will pay any selling commissions and expenses they
may incur for brokerage, accounting, tax, legal services or other expenses
relating to the disposition of their shares, as well as any transfer taxes on
the shares that they sell. We will bear all other costs, fees and expenses
relating to the registration of the shares, including, without limitation, all
registration and filing fees, Nasdaq listing fees, fees and expenses of our
counsel, fees of our accountants, and blue sky fees and expenses.
17
<Page>
SELLING SHAREHOLDERS
The Selling Shareholders are offering up to 1,350,000 shares of common
stock. Of these:
100,000 shares are issuable to seven Selling Shareholders should they
exercise outstanding common stock purchase warrants exercisable at a price
of $1.25 per share;
50,000 shares are issuable to seven Selling Shareholders should they
exercise outstanding warrants to purchase common stock exercisable at a
price of $1.50 per share;
1,000,000 shares are issuable to five Selling Shareholders should they
convert Series 2002A 4% Convertible Promissory Notes into common stock at a
price of $1.00 per share or should we repay the promissory notes by issuing
shares of our common stock; and
200,000 shares are issuable to five Selling Shareholders should they
exercise outstanding warrants to purchase common stock exercisable at a
price of $1.25 per share, which warrants were granted in connection with
the 2002A 4% Convertible Promissory Notes.
We have a right to repay the promissory notes in cash, but if we do so, we
have an obligation to issue up to an additional 1,000,000 common stock purchase
warrants (exercisable at $1.00) at the rate of one warrant for each $1.00 in
principal cash payment. If we issue these warrants, we will not issue the
1,000,000 shares to holders of the Series 2002A 4% Convertible Promissory Notes
because they will not have converted those Notes.
We have set forth in the following table, to our knowledge, information
about the selling stockholders as of April 12, 2002, or such later date as the
selling stockholders have provided the information. We have calculated
beneficial ownership based on SEC requirements, and the information we have
included regarding beneficial ownership is not necessarily indicative of
beneficial ownership for any other purpose. Unless we otherwise indicate below,
each stockholder named in the table has sole voting and investment power with
respect to all shares he, she or it beneficially owns, subject to applicable
community property laws. We have based the percentage calculated for each
selling stockholder upon the sum of the "Common Stock" and "Common Stock
Issuable Upon Exercise of Warrants and Conversion or Payment of Notes" columns.
Percentages in the below table were calculated using a denominator equal to
the total number of shares outstanding (10,824,812 as of April 12, 2002) plus
the number of convertible securities and common stock purchase warrants included
in the numerator.
None of the Selling Shareholders has had any material relationship with
Isonics during the past three years except in connection with the investment
banking agreement that resulted in the issuance of 50,000 common stock purchase
warrants (exercisable at $1.50) and payment of additional consideration.
We do not know when or in what amounts the Selling Shareholders may offer
Shares for sale. The Selling Shareholders may decide not to sell all or any of
the shares that this prospectus covers. Because the Selling Stockholders may
offer all or some of the shares pursuant to this offering, and because there are
currently no agreements, arrangements or understandings with respect to the sale
of any of the shares that the Selling Shareholders will hold after completion of
the offering, we cannot estimate the number of the shares that the Selling
Shareholders will hold after completion of the offering. However, for purposes
of
18
<Page>
this table, we have assumed that, after completion of the offering, the Selling
Shareholders will hold none of the shares that this prospectus covers.
<Table>
<Caption>
- ----------------------------------------------------------------------------------------------------------------
Name of Selling Common Stock Beneficially Owned Prior Common Stock Common Stock to be Beneficially
Shareholder(s) to Offering Offered Owned After Offering Assuming All
Pursuant to Shares Offered are Sold
this
Prospectus
-------------------------------------- ------------ ---------------------------------
Common Common Common Stock Common Stock Percent
Stock Stock Issuable upon
owned Issuable Conversion or
upon Payment of
exercise of Notes
Warrants
- --------------------- --------- ----------- ------------- ------------ ------------- -----------------
Alpha Capital A.G., -0- 60,000 300,000 360,000
a Lichtenstein
Corporation (1)
Boat Basin -0- 50,000 250,000 300,000
Investors LLC, a
St. Kitts & Nevis
Limited Liability
Company (1)
Vincent Calicchia -0- 12,500 -0- 12,500
(2)
Tim Mahoney (2) -0- 10,000 -0- 10,000
Richard Rosenblum -0- 30,000 -0- 30,000
(2)
Mark Siegel (2) -0- 20,000 50,000 70,000
Leonard Sokolow (2) -0- 20,000 50,000 70,000
David Stefansky (2) -0- 30,000 -0- 30,000
Stone Street -0- 70,000 350,000 420,000
Limited
Partnership, an
Ontario Limited
Partnership (1)
vFinance, Inc. (2) -0- 47,500 -0- 47,500
- ----------------------------------------------------------------------------------------------------------------
</Table>
19
<Page>
(1) In the case of Alpha Capital A.G., Boat Basin Investors LLC, and Stone
Street Limited Partnership, the warrants are each exercisable for $1.25 per
share and expire March 20, 2005. The promissory notes are convertible at
$1.00 per share, and the amount includes only the face value of the
promissory notes. Although the notes provide that we may issue shares of
stock to repay the promissory notes, we are not registerting the issuance
of the shares in this prospectus, but rather the ability of the Selling
Shareholders to transfer the shares once issued. The initial issuance of
the shares to the Selling Shareholders upon exercise of the warrants or
conversion of the Series 2002A 4% convertible promissory notes can only be
accomplished pursuant to an exemption from registration.
(2) In the case of Messrs. Calicchia, Mahoney, Rosenblum, Siegel, Sokolow and
Stefansky, and vFinance, Inc., the securities consist of warrants
exericisable at both $1.25 per share and $1.50 per share, and in some cases
convertible promissory notes, as follows:
<Table>
<Caption>
- ----------------------------------------------------------------------------
Exercise or
Warrants or Notes Number Conversion Price
----------------- ------ ----------------
Mr. Calicchia Warrants 8,333 $1.25
4,167 $1.50
Mr. Mahoney Warrants 6,667 $1.25
3,333 $1.50
Mr. Rosenblum Warrants 20,000 $1.25
10,000 $1.50
Mr. Siegel Warrants 16,667 $1.25
3,333 $1.50
Note 50,000 $1.00
Mr. Sokolow Warrants 16,667 $1.25
3,333 $1.50
Note 50,000 $1.00
Mr. Stefansky Warrants 20,000 $1.25
10,000 $1.50
vFinance Warrants 31,666 $1.25
15,834 $1.50
- ----------------------------------------------------------------------------
</Table>
Based on information the Selling Shareholders have given to us, none of the
Selling Shareholders own, directly or indirectly, shares of our Common Stock
other than listed above.
The foregoing tables also do not include 1,000,000 shares included in this
Prospectus underlying common stock purchase warrants (exercisable at $1.00 per
share) that we will have to issue to the extent that we repay any portion of the
outstanding promissory notes in cash. We must issue one common stock purchase
warrant for each $1.00 cash payment that we make.
PLAN OF DISTRIBUTION
The Selling Shareholders may, from time to time, offer and sell the shares
included in this prospectus. The term "Selling Stockholders" includes pledgees,
donees, transferees or other successors in interest selling shares that they
acquired after the date of this prospectus from the Selling Shareholders as a
20
<Page>
pledge, gift or other non-sale related transfer. To the extent required, we may
amend and supplement this prospectus from time to time to describe a specific
plan of distribution.
The Selling Shareholders will act independently of us in making decisions
with respect to the timing, manner and size of each sale. The Selling
Shareholders may make these sales at prices and under terms then prevailing or
at prices related to the then current market price. The Selling Shareholders may
also make sales in negotiated transactions, including pursuant to one or more of
the following methods:
o purchases by a broker-dealer as principal and resale by such
broker-dealer for its own account pursuant to this prospectus;
o ordinary brokerage transactions and transactions in which the broker
solicits purchasers;
o block trades in which the broker-dealer will attempt to sell the
shares as agent but may position and resell a portion of the block as
principal to facilitate the transaction;
o an over-the-counter distribution in accordance with the rules of the
Nasdaq SmallCap Market; and
o in privately negotiated transactions.
In connection with distributions of the shares or otherwise, the Selling
Shareholders may:
o enter into hedging transactions with broker-dealers or other financial
institutions, which may in turn engage in short sales of the shares in
the course of hedging the positions they assume;
o sell the shares short and redeliver the shares to close out such short
positions;
o enter into option or other transactions with broker-dealers or other
financial institutions which require the delivery to them of shares
that this prospectus offers, which they may in turn resell; and
o pledge shares to a broker-dealer or other financial institution,
which, upon a default, they may in turn resell.
In addition, the Selling Shareholders may sell any shares that qualify for
sale pursuant to Rule 144 under Rule 144 rather than pursuant to this
prospectus.
In effecting sales, broker-dealers or agents that the Selling Shareholders
engage may arrange for other broker-dealers to participate. Broker-dealers or
agents may receive commissions, discounts or concessions from the Selling
Shareholders, in amounts that the parties may negotiate immediately prior to the
sale.
In offering shares that this prospectus covers, the Selling Shareholders,
and any broker-dealers and any other participating broker-dealers who execute
sales for the Selling Shareholders, may qualify as "underwriters" within the
meaning of the Securities Act in connection with these sales. Any profits that
the Selling Shareholders realize, and the compensation that they pay to any
broker-dealer, may qualify as underwriting discounts and commissions.
21
<Page>
In order to comply with the securities laws of some states, the Selling
Shareholders must sell the shares in those states only through registered or
licensed brokers or dealers. In addition, in some states the Selling
Shareholders must sell the shares only if we have registered or qualified those
shares for sale in the applicable state or an exemption from the registration or
qualification requirement is available and the Selling Shareholder complies with
the exemption.
We will advise the Selling Shareholders that the anti-manipulation rules of
Regulation M under the Exchange Act may apply to sales of shares in the market
and to the activities of the Selling Shareholders and their affiliates. In
addition, we will make copies of this prospectus available to the Selling
Shareholders for the purpose of satisfying the prospectus delivery requirements
of the Securities Act. The Selling Shareholders may indemnify any broker-dealer
that participates in transactions involving the sale of the shares against
liabilities, including liabilities arising under the Securities Act.
At the time a Selling Shareholder makes a particular offer of shares, if
required, we will distribute a prospectus supplement that will set forth:
o the number of shares that the Selling Shareholder is offering;
o the terms of the offering, including the name of any underwriter,
dealer or agent;
o the purchase price paid by any underwriter;
o any discount, commission and other underwriter compensation;
o any discount, commission or concession allowed or reallowed or paid to
any dealer; and
o the proposed selling price to the public.
We have agreed to indemnify the Selling Shareholders against certain
liabilities, and each of the Selling Shareholders has agreed to indemnify us
against certain liabilities, in both cases including liabilities under the
Securities Act.
DESCRIPTION OF SECURITIES
Our authorized capital stock consists of 40,000,000 shares of Common Stock
and 10,000,000 shares of Preferred Stock. As of April 12, 2002, there were
outstanding:
10,824,812 shares of Common Stock
963,666 shares of Series A Convertible Preferred Stock convertible into
common stock at the rate of 1.50 shares of common stock for each share of
Series A Convertible Preferred Stock
1,000,000 shares issuable upon conversion or payment of our Series 2002A
convertible promissory notes
22
<Page>
1,568,473 shares issuable upon exercise of options issued pursuant to our
employee benefit plans
6,178,232 shares issuable upon exercise of outstanding warrants
COMMON STOCK
Subject to preferences that may be applicable to any Preferred Stock
outstanding at the time, the holders of outstanding shares of Common Stock are
entitled to receive dividends out of assets legally available therefore at such
times and in such amounts as the Board of Directors may from time to time
determine.
Each shareholder is entitled to one vote for each share of Common Stock
held on all matters submitted to a vote of shareholders.
Cumulative voting for the election of directors is specifically authorized
by the Bylaws. Under cumulative voting for the election of directors, upon a
proper and timely request by a shareholder, each shareholder is entitled to cast
a number of votes equal to the number of shares held multiplied by the number of
directors to be elected. The votes may be cast for one or more candidates. Thus,
under cumulative voting, a majority of the outstanding shares will not
necessarily be able to elect all of the directors, and minority shareholders may
be entitled to greater voting power with respect to election of directors than
if cumulative voting did not apply.
The Bylaws provide that so long as we are a "listed company" as defined by
applicable California law, there will not be cumulative voting in connection
with the election of directors. At the present time however, we are not a
"listed company" as defined in California law, and as a result cumulative voting
will continue to apply in connection with the election of directors.
The Common Stock is not entitled to preemptive rights and is not subject to
conversion or redemption. Upon liquidation, dissolution or winding up of
Isonics, the remaining assets legally available for distribution to
shareholders, after payment of claims or creditors and payment of liquidation
preferences, if any, on outstanding Preferred Stock, are distributable ratably
among the holders of the Common Stock and any participating Preferred Stock
outstanding at that time. Each outstanding share of Common Stock is fully paid
and nonassessable.
WARRANTS
The warrants are exercisable to purchase shares of common stock until March
20, 2005 at prices of either $1.25 or $1.50. The warrants are exercisable for
cash only. There are no conversion rights or exchange rights associated with the
warrants. The warrants are subject to standard dilution adjustment.
2002A 4% CONVERTIBLE PROMISSORY NOTE
The 2002A 4% Convertible Promissory Notes are due on March 1, 2003 and
contain standard default provisions should we fail to comply with any of the
terms of the promissory notes. In addition, if this prospectus is not effective
by June 14, 2002, the holders may declare the promissory notes to be in default
and, among other remedies, foreclose against the shares pledged as collateral by
Messrs. Alexander and Rubizhevsky. It will not be considered an event of default
to the extent any delay in the effectiveness of the Registration Statement
occurs because of an act of, or a failure to act or to act timely by any of the
Selling Shareholders or their counsel.
23
<Page>
We have the ability to repay these notes in cash or in shares of our common
stock (at $1.00 per share), so long as the shares are registered. To the extent
that we repay the notes in cash, we are obligated to issue warrants to the
holder entitling them to purchase shares of our common stock at $1.00 per share
for each $1.00 of cash repayment. Each note is convertible into shares of our
common stock at $1.00 per share, and various obligations of the notes are
guaranteed by James E. Alexander (our president) and Boris Rubizhevsky (our
senior vice president). They each pledged 500,000 shares of our common stock
they own to secure these obligations (a total of 1,000,000 shares). We also
issued each lender a warrant to acquire one share of our restricted common stock
for each $5.00 loaned to us.
TRANSFER AGENT
The transfer agent for our Common Stock is Continental Stock Transfer &
Trust Co., 17 Battery Place, 8th Floor, New York, NY 10004.
SECURITIES AND EXCHANGE COMMISSION POSITION ON INDEMNIFICATION FOR
SECURITIES ACT LIABILITIES
The Articles of Incorporation of Isonics require it to indemnify its
officers, directors, employees and agents against certain liabilities incurred
by them in those capacities if they acted in good faith and reasonably believed
their conduct was in the best interests of Isonics or not opposed to it. Isonics
is also required to indemnify a person who is or was a director, officer,
employee or agent of Isonics and who was successful, on the merits or otherwise,
in defense of any proceeding to which he was a party, against reasonable
expenses, which include attorneys' fees, incurred by him or her in connection
with the proceeding.
Insofar as indemnification for liabilities arising under the Securities Act
of 1933 may be permitted to directors, officers and controlling persons of
Isonics under the provisions discussed in the previous paragraph, or otherwise,
Isonics has been advised that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as expressed in that
Act and is, therefore, unenforceable.
EXPERTS
The consolidated financial statements included in the Annual Report on Form
10-KSB of Isonics Corporation for the year ended April 30, 2001, which have been
incorporated by reference in this registration statement, have been so
incorporated in reliance on the report of Grant Thornton LLP, independent
certified public accountants, given on the authority of said firm as experts in
accounting and auditing.
LEGAL MATTERS
Certain legal matters have been passed upon for Isonics by Burns, Figa &
Will, P.C., Englewood, Colorado. The validity of the shares of Common Stock
offered hereby has been passed upon as to matters of California law by Arter &
Hadden, LLP, Los Angeles, California.
24
<Page>
Back Cover Page of Prospectus
NO PERSON HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION OR MAKE ANY
REPRESENTATIONS NOT CONTAINED IN THIS PROSPECTUS AND, IF GIVEN OR MADE, SUCH
INFORMATION OR REPRESENTATIONS MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED
BY ISONICS. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO SELL OR SOLICITATION
OF AN OFFER TO BUY ANY OF THE SECURITIES TO ANY PERSON IN ANY JURISDICTION WHERE
SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL. THE DELIVERY OF THIS PROSPECTUS AT
ANY TIME DOES NOT IMPLY THAT THE INFORMATION HEREIN IS CORRECT AS OF ANY TIME
SUBSEQUENT TO ITS DATE
<Table>
<Caption>
Page
-----
How to Obtain Additional Information 5
Documents Incorporated by Reference 5
Note of Caution Regarding Forward Looking Statements 6
Prospectus Summary 7
Risk Factors 8
Who We Are 16
Use of Proceeds 17
Selling Shareholders 18
Plan of Distribution 20
Description of Securities 22
Securities and Exchange Commission Position on Indemnification
for Securities Act Liabilities 24
Experts 24
Legal Matters 24
</Table>
25
<Page>
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution.
The following is an itemization of all expenses (subject to future
contingencies) incurred or to be incurred by the Registrant in connection with
the issuance and distribution of the securities being offered. All expenses are
estimated except the registration fee.
<Table>
- ----------------------------------------------
Registration and filing fee $ 77
Printing $ 6,000
Accounting fees and expenses $ 5,000
Legal fees and expenses $10,000
Blue sky filing fees and expenses $ 5,000
Transfer and Warrant Agent fees $ 1,000
Miscellaneous $ 2,923
-------
Total $30,000
- ----------------------------------------------
</Table>
Item 15. Indemnification of Directors and Officers.
The Articles of Incorporation of Isonics include a provision that
eliminates to the fullest extent permitted by law the personal liability of its
directors to Isonics and its shareholders for monetary damages for breach of the
directors' fiduciary duties. This limitation has no effect on a director's
liability
o for acts or omissions that involve intentional misconduct or a knowing
and culpable violation of law;
o for acts or omissions that a director believes to be contrary to the
best interests of Isonics or its shareholders or that involved the
absence of good faith on the part of the director;
o for any transaction from which the director derived an improper
personal benefit;
o for acts or omissions that show a reckless disregard for the
director's duty to Isonics or its shareholders in circumstances in
which the director was aware, or should have been aware, in the
ordinary course of performing a director's duties, of a risk of
serious injury to Isonics or its shareholders; and
o for acts or omissions that constitute an unexcused pattern of
inattention that amounts to an abdication of the director's duty to
Isonics or its shareholders, under Section 310 of the California
Corporations Code (the "California Code") concerning contracts or
transactions between Isonics and a director or under Section 316 of
the California Code concerning directors liability for improper
dividends, loans and guarantees.
26
<Page>
The provision does not extend to acts or omissions of a director in his
capacity as an officer. Further, the provision will not affect the availability
of injunctions and other equitable remedies available to Isonics' shareholders
for any violation of a director's fiduciary duty to Isonics or its shareholders.
The Articles of Incorporation further authorize Isonics to indemnify its
agents (as defined in Section 317(a) of the Code which includes directors and
officers) through Bylaw provisions, agreements with agents, votes of
shareholders or disinterested directors or otherwise, to the fullest extent
permissible under California law. Pursuant to this provision, the Bylaws of
Isonics provide for indemnification of directors and officers. The Bylaws also
permit Isonics to enter into indemnity agreements with individual directors,
officers, employees and other agents. Isonics intends to enter into such
agreements with its directors and executive officers effective upon the closing
of this offering. These Agreements, together with the Bylaws and Articles of
Incorporation, may require Isonics, among other things, to indemnify directors
or officers against certain liabilities that may arise by reason of their status
or service as directors (other than liabilities resulting from willful
misconduct of a culpable nature), to advance expenses to them as they are
incurred, provided that they undertake to repay the amount advanced if it is
ultimately determined by a court that they are not entitled to indemnification,
and to obtain and maintain directors' and officers' insurance if available on
reasonable terms.
In addition to the rights to indemnification provided under California law,
in the Articles of Incorporation and in the Bylaws, the 1996 Stock Option Plan
provides indemnification to members of the Board of Directors, officers, or
employees of Isonics to whom authority to act for the Board in connection with
the Existing Plan is delegated shall be indemnified against all reasonable
expenses, including attorneys' fees, actually and necessarily incurred in
defense of any proceeding to which he or she is made a party because of any
action allegedly taken or alleged failure to act in connection with the Plan,
and against amounts paid in settlement (if approved by independent legal
counsel), or in satisfaction of any judgment in such proceeding, unless the
director, officer, or employee, as the case may be, is adjudged to have behaved
in bad faith, in a grossly negligent manner, or with intentional misconduct as
to duties.
Isonics currently has directors and officers' liability insurance.
At present, there is no pending litigation or proceeding involving a
director, officer or employee of Isonics pursuant to which indemnification is
sought, nor is Isonics aware of any threatened litigation that may result in
claims for indemnification.
Section 317 of the Code and the Bylaws of Isonics make provision for the
indemnification of officers, directors and other corporate agents in terms
sufficiently broad to indemnify such persons, under certain circumstances, for
liabilities (including reimbursement of expenses incurred) arising under the
Securities Act. Insofar as indemnification for liabilities arising under the
Securities Act may be permitted to directors, officers and controlling persons
pursuant to the foregoing provisions, or otherwise, Isonics has been advised
that in the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in the Securities Act and
is, therefore, unenforceable.
Reference is made to the following documents filed as exhibits to this
Registration Statement regarding relevant indemnification provisions described
above and elsewhere herein:
27
<Page>
<Table>
<Caption>
Document Exhibit Number
- -------- --------------
Underwriting Agreement 1.01
Registrant's Certificate of Incorporation 3.01
Registrant's Bylaws 3.02
Form of Indemnity Agreement 10.09
</Table>
Item 16. Exhibits and Financial Statement Schedules.
(a) Exhibits Pursuant to Item 601 of Regulation S-B:
<Table>
<Caption>
EXHIBIT
NUMBER TITLE
- ------- -----
1.01 Form of Underwriting Agreement. (1)
3.01 Registrant's Amended and Restated Articles of Incorporation. (1)
3.02 Registrant's Bylaws. (1)
3.03 Certificate of Determination of Preferences and Rights of the Series A
preferred stock (see exhibit 10.18).
3.04 Certificate Of Determination Of Preferences And Rights Of Series B
Convertible Preferred Stock(11)
3.05 Certificate of Amendment to Articles of Incorporation(13)
4.01 Specimen Common Stock Certificate. (1)
4.02 Form of Representatives' warrant Agreement. (1)
4.03 Form of warrant Agreement between the Registrant and Continental Stock
Transfer & Trust Company, Monroe Parker Securities. (1)
4.04 Form of warrant Agreement between the Registrant and Continental Stock
Transfer & Trust Company. (8)
4.05 Amendment No. 1 to warrant Agreement between the Registrant and
Continental Stock Transfer & Trust Company. (7)
5.01* Opinion of Arter & Hadden, LLP, as to legality of securities
10.01 Registrant's 1996 Stock Option Plan. (1)(2)
10.02 Form of Employment Agreement between the Registrant and certain
officers of the Registrant. (1)(2)
10.03 Registrant's 1996 Executives Equity Incentive Plan. (1)(2)
10.04 Registrant's 1996 Equity Incentive Plan. (1)(2)
10.05 Memorandum of Agreement between Electrochemical Plant, AO
Techsnabexport, Co., Ltd. and Registrant. (1)
10.06 Option Agreement between the Registrant and Yale University. (1)
10.07 Office Lease Agreement between Paulsen Properties and the Registrant
dated as of January 1, 1996, as amended. (1)
10.08 Letter from Yale University to Registrant dated February 10, 1996. (1)
10.09 Form of Indemnity Agreement entered into by Registrant with each of
its directors and investors. (2)
10.10 Stock Purchase Agreement, dated as of April 30, 1998, among Isonics
Corporation, a California corporation, Metallurgy International, Inc.,
a Nevada corporation, and International Process Research Corporation,
a Colorado corporation. (3)
10.10.1 Escrow Agreement, dated as of May 15, 1998, among Isonics Corporation,
a California corporation, Metallurgy International, Inc., a Nevada
corporation, Robert H. Cuttriss (as Agent), and Colorado Business
Bank, as Escrow Agent. (3)
10.11 Registration Rights Agreement dated as of September 27, 1996 by and
between Registrant and certain investors. (1)
10.12 Employment Agreement between the Registrant and James E. Alexander. (1)(2)
10.13 Employment Agreement between the Registrant and Boris Rubizhevsky. (1)(2)
</Table>
28
<Page>
<Table>
<Caption>
EXHIBIT
NUMBER TITLE
- ------- -----
10.14 Security Agreement dated March 31, 1995 between Isonics and Isoserve, Inc. (1)
10.15
10.16 February 1997 Agreement between the Registrant, Electrochemical Plant
and AO Techsnabexport, Co., Ltd. (1)
10.17 Letter from Yale University to Registrant dated January 28, 1997. (1)
10.18 Certificate of Determination of Preferences and Rights of the Series A
preferred stock. (4)
10.19 Form of Subscription Agreement (7-29-1999 transaction). (4)
10.20 Form of warrant (7-29-1999 transaction). (4)
10.21 Investment Banking Agreement (7-29-1999 transaction). (4)
10.22 Form of Registration Rights Agreement (7-29-1999 transaction). (4)
10.23 Asset Purchase Agreement dated December 1, 1999 between the Registrant
and Eagle-Picher Technologies, LLC. (5)
10.24 Registration Rights Agreement dated December 1, 1999 between the
Registrant and Eagle-Picher Technologies, LLC. (5)
10.25 Warrant Agreement dated December 1, 1999 between the Registrant and
Eagle-Picher Technologies, LLC. (5)
10.26 Supply Agreement between the Registrant and Eagle-Picher Technologies, LLC. (6)
10.27 Amended and Restated warrant Agreement effective as of January 15,
2001, between the Registrant and Continental Stock Transfer and Trust
Company, Inc. (8)
10.28 Stock Purchase Agreement dated February 1, 2001, by and between
Isonics Corporation and Interpro Zinc, LLC. (9)
10.29 Joint R&D Project Agreement, dated April 21, 1999, by and between
Silex Systems Limited and Isonics Corporation. (10)
10.30 Contribution to "Corporate Research - ECE/Baliga" fund dated December
30, 1999, from Isonics Corporation to North Carolina State University. (10)
10.31 Sponsored Research Agreement, dated December 15, 1999, by and between
Isonics Corporation and Southern Methodist University. (10)
10.32 Stevenson-Wydler Cooperative Research and Development Agreement, dated
November 9, 1999, by and between Ernest Orlando Lawrence Berkeley
National Laboratory and Isonics Corporation (with attached Project
Letter Agreement). (10)
10.33 Memorandum of Agreement, dated July 1996, by and among Electrochemical
Plant, AO Techsnabexport Co., Ltd. And A & R Materials, Inc. (10)
10.34 Agreement between Isonics Corporation and Silicon Evolution, Inc.
dated September 14, 2001 (12)
10.35 Technology License Agreement dated September 14, 2001, between Silicon
Evolution, Inc. and Isonics Corporation (12)
10.36 Form of employment agreement to be entered into pursuant to the
agreement between Isonics Corporation and Silicon Evolution, Inc.
dated September 14, 2001 (12)
10.37 Form of lease agreement to be entered into pursuant to the agreement
between Isonics Corporation and Silicon Evolution, Inc. dated
September 14, 2001 (12)
10.38 Amended and Restated Warrant Agreement dated July 26, 2001. (11)
10.39 Consulting Agreement dated October 15, 2001, with Wells Investment Group(13)
10.40 Form of Registration Rights Agreement (3-22-2002 transaction) (14)
10.41 Form of Series 2002A 4% Convertible Promissory Note due March 1, 2003
(3-22-2002 transaction) (14)
10.42 Form of Warrant Agreement expiring March 20, 2005 (3-22-2002
transaction) (14)
21.01 List of subsidiaries.
23.01* Consent of independent accountants
23.02 Consent of Arter & Hadden, LLP (see exhibit 5.01)
</Table>
29
<Page>
* Filed herewith. All other documents have been previously filed.
(1) Incorporated herein by reference to exhibit filed with Isonics'
Registration Statement on Form SB-2 ("Registration Statement") (Commission
file No. 333-13289) in which this exhibit bears the same number except
exhibit 3.01, which was numbered 3.03 in that registration statement.
(2) Items that are management contracts or compensatory plans or arrangements
required to be filed as exhibits pursuant to Item 13(a) of Form 10-KSB.
(3) Filed with Isonics' Current Report on Form 8-K (File No. 001-12531), dated
May 15 and filed May 27, 1998, and incorporated herein by reference.
(4) Filed with Isonics' Current Report on Form 8-K (File No. 001-12531), dated
July 29 and filed August 12, 1999, and incorporated herein by reference.
(5) Filed with Isonics' Current Report on Form 8-K (File No. 001-12531) dated
December 1, 1999, and filed December 10, 1999, and amendment thereto filed
February 10, 2000, and incorporated herein by reference.
(6) Confidential treatment obtained.
(7) Filed with Isonics' Current Report on Form 8-K (File No. 001-12531) dated
August 17, 2000, and filed August 18, 2000, and incorporated herein by
reference.
(8) Filed with Isonics' registration statement on Form S-4 (File No. 333-37696)
or the amendments thereto, and incorporated herein by reference.
(9) Filed with Isonics' Current Report on Form 8-K (File No. 001-12531) dated
February 1, 2001, and incorporated herein by reference.
(10) Filed with Isonics' annual report on Form 10-KSB (File No. 001-12531) for
the year ended April 30, 2001, and incorporated herein by reference.
(11) Filed with Isonics' Form 8-A/12(g) filed on August 1, 2001.
(12) Filed with Amendment no. 2 to registration statement (File No. 333-56562)
and incorporated herein by reference.
(13) Filed with Isonics' Form 8-K (File No. 001-12531) dated January 8, 2002 and
incorporated herein by reference.
(14) Filed with Isonics' Form 8-K (File No. 001-12531) dated March 22, 2002 and
incorporated herein by reference.
Item 17. Undertakings.
The undersigned Registrant hereby undertakes: (1) to file, during any
period in which offers or sales are being made, a post-effective amendment to
the Registration Statement: (i) to include any prospectus required by Section
10(a)(3) of the Securities Act of 1933; (ii) to reflect in the prospectus any
facts or events arising after the effective date of the Registration Statement
(or the most recent post-effective amendment thereof) which, individually or in
the aggregate, represent a fundamental change in the information set forth in
the Registration Statement; and (iii) to include any material information with
respect to the plan of distribution not previously disclosed in the Registration
Statement or any material change to the information in the Registration
Statement, including (but not limited to) any addition or deletion of a managing
underwriter; (2) that for the purpose of determining any liability under the
Securities Act of 1933, each post-effective amendment shall be deemed to be a
new registration statement relating to the securities offered therein, and the
offering of securities at that time shall be deemed to be the initial bona fide
offering thereof; and (3) to remove from registration by means of a
post-effective amendment any of the securities being registered which remain
unsold at the termination of the offering.
30
<Page>
The undersigned Registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act of 1933, each filing of the
Registrant's Annual Report pursuant to section 13(a) or section 15(d) of the
Securities Exchange Act of 1934 (and, where applicable, each filing of an
employee benefit plan's annual report pursuant to section 15(d) of the
Securities Exchange Act of 1934) that is incorporated by reference in the
registration statement shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of securities at
that time shall be deemed to be the initial bona fide offering thereof.
The undersigned Registrant hereby undertakes to deliver or cause to be
delivered with the prospectus, to each person to whom the prospectus is sent or
given, the latest annual report to security holders that is incorporated by
reference in the prospectus and furnished pursuant to and meeting the
requirements of Rule 14a-3 or Rule 14c-3 under the Securities Exchange Act of
1934; and, where interim financial information required to be presented by
Article 3 of Regulation S-X are not set forth in the prospectus, to deliver, or
cause to be delivered, to each person to whom the prospectus is sent or given,
the latest quarterly report that is specifically incorporated by reference in
the prospectus to provide such interim financial information.
Insofar as indemnification for liabilities arising under the Securities Act
of 1933 may be permitted to directors, officers and controlling persons of the
registrant pursuant to the Registrant's Articles of Incorporation, or otherwise,
the Registrant has been advised that in the opinion of the Securities and
Exchange Commission indemnification is against public policy as expressed in the
Act and is, therefore, unenforceable. In the event that a claim for
indemnification against liabilities (other than the payment by the Registrant of
expenses incurred or paid by a director, officer or controlling person of the
Registrant in the successful defense of any action, suit or proceeding) is
asserted by a director, officer or controlling person in connection with the
securities being registered, the Registrant will, unless in the opinion of its
counsel the matter has been settled by controlling precedent, submit to a court
of appropriate jurisdiction the question whether such indemnification by it is
against public policy as expressed in the Act and will be governed by the final
adjudication of such issue.
31
<Page>
SIGNATURE
Pursuant to the requirements of the Securities Act of 1933, the Registrant
certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-3 and has duly caused this Registration
Statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in Golden, Jefferson County, State of Colorado, on April 24, 2002.
ISONICS CORPORATION
By: /s/ James E. Alexander
---------------------------
James E. Alexander, President
In accordance with the requirements of the Securities Act of 1933, the
following persons in their capacities and on the dates stated signed this
registration statement.
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature
appears constitutes and appoints James E. Alexander and Boris Rubizhevsky, or
either of them, as true and lawful attorneys-in-fact and agents with full power
of substitution and re-substitution, for him and in his name, place and stead,
in any and all capacities to sign the Registration Statement file herewith and
any or all amendments to said Registration Statement (including post-effective
amendments and registration statements filed pursuant to Rule 462 and
otherwise), and to file the same, with all exhibits thereto, and other documents
in connection therewith, the Securities and Exchange Commission granting unto
said attorney-in-fact and agents the full power and authority to do and perform
each and every act and thing requisite and necessary to be done in and about the
foregoing, as to all intents and purposes as he or she might or could do in
person, hereby ratifying and confirming all that said attorney-in-fact and
agents or any of them, or his substitute, may lawfully do or cause to be done by
virtue hereof.
/s/ James E. Alexander President, Chief Executive April 24, 2002
- ---------------------- Officer, Chairman and Director
/s/ Boris Rubizhevsky Senior Vice President and April 24, 2002
- ---------------------- Director
/s/ Lindsay A. Gardner Director April 24, 2002
- ----------------------
/s/ Richard Parker Director April 24, 2002
- ----------------------
/s/ Larry J. Wells Director April 24, 2002
- ----------------------
/s/ John V. Sakys Chief Financial Officer April 24, 2002
- ----------------------
32